> top > docs > PMC:7796052 > spans > 12392-13095 > annotations

PMC:7796052 / 12392-13095 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
330 158-162 Gene denotes IL-6 Gene:3569
331 163-168 Gene denotes STAT3 Gene:6774
332 266-275 Species denotes SARS-Cov2 Tax:2697049
333 363-374 Species denotes ebola virus Tax:205488
334 670-678 Species denotes patients Tax:9606
335 74-84 Chemical denotes raloxifene MESH:D020849
336 243-253 Chemical denotes ralixofene
337 457-467 Chemical denotes ralidoxene
338 647-657 Chemical denotes ralixofene
339 106-114 Disease denotes Covid-19 MESH:C000657245
340 571-579 Disease denotes Covid-19 MESH:C000657245
341 661-669 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T79 0-195 Sentence denotes The results of this work complement recent comments suggesting the use of raloxifene for the treatment of Covid-19 [45], based on its capacity to inhibit the IL-6/STAT3 signaling pathway [46,47].
T80 196-400 Sentence denotes In addition, the presumed antiviral profile of ralixofene against the SARS-Cov2 virus through its capability to block the two-pore channel TCP2 [48], as found for the ebola virus [49] has been underlined.
T81 401-580 Sentence denotes In conclusion, the pharmacodynamic profile exhibited by ralidoxene described in the present report represents a reasonable base to test the compound for the treatment of Covid-19.
T82 581-703 Sentence denotes Very recently a clinical trial in Italy has been approved to test ralixofene in COVID-19 patients with mild symptoms [50].